Drug Interactions between Aptivus and voriconazole
This report displays the potential drug interactions for the following 2 drugs:
- Aptivus (tipranavir)
- voriconazole
Interactions between your drugs
voriconazole tipranavir
Applies to: voriconazole and Aptivus (tipranavir)
ADJUST DOSE: Coadministration with azole antifungal agents may substantially increase the plasma concentrations of tipranavir administered in combination with low-dose ritonavir. The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of both tipranavir and ritonavir. In 20 study subjects, fluconazole (100 mg once a day for 12 days) increased the mean peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and trough plasma concentration (Cmin) of steady-state tipranavir (500 mg with ritonavir 200 mg twice a day) by 32%, 50% and 69%, respectively, compared to historical data. Tipranavir/ritonavir had negligible effects on fluconazole. The interaction has not been studied with other azole antifungal agents but is expected to occur due to their potent inhibitory effects on CYP450 3A4.
MANAGEMENT: In patients treated with tipranavir/ritonavir, dosages of fluconazole, itraconazole, and ketoconazole exceeding 200 mg/day are not recommended. Due to multiple enzymes involved with voriconazole metabolism, the interaction is difficult to predict and no recommendations are available.
References (1)
- (2005) "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim
Drug and food interactions
voriconazole food
Applies to: voriconazole
ADJUST DOSING INTERVAL: Food reduces the oral absorption and bioavailability of voriconazole. According to the product labeling, administration of multiple doses of voriconazole with high-fat meals decreased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 34% and 24%, respectively, when the drug is administered as a tablet, and by 58% and 37%, respectively, when administered as the oral suspension.
MANAGEMENT: To ensure maximal oral absorption, voriconazole tablets and oral suspension should be taken at least one hour before or after a meal.
References (2)
- (2002) "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
tipranavir food
Applies to: Aptivus (tipranavir)
ADJUST DOSING INTERVAL: Food does not appear to substantially alter the pharmacokinetics of tipranavir. When tipranavir capsules or oral solution was coadministered with ritonavir capsules at steady-state, no clinically significant changes in tipranavir peak plasma concentration (Cmax) and systemic exposure (AUC) were observed under fed conditions (500 to 682 kcal, 23% to 25% calories from fat) relative to fasted conditions. The effect of food on tipranavir exposure during coadministration with ritonavir tablets has not been evaluated. High-fat foods may enhance the gastrointestinal absorption of tipranavir. In a multiple-dose study, administration of tipranavir capsules with a high-fat meal (868 kcal, 53% from fat, 31% from carbohydrates) increased the oral bioavailability of tipranavir by 31% compared to administration with toast and skimmed milk, but did not significantly affect tipranavir Cmax. Thus, tipranavir may be safely taken with standard or high-fat meals.
MANAGEMENT: Tipranavir coadministered with low-dose ritonavir should be taken with food to improve the gastrointestinal tolerability of ritonavir. According to the product labeling, tipranavir coadministered with ritonavir capsules or solution can be taken with or without meals, whereas tipranavir coadministered with ritonavir tablets must be taken with meals.
References (4)
- (2005) "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.